哲源科技完成亿元A1轮融资，聚焦“AI4S+疾病”赛道

Core Insights - Beijing Zheyuan Technology Co., Ltd. announced the completion of A1 round financing amounting to 1 billion yuan [1] - The financing was led by Guokai Investment, with participation from Zeyuan Fund and Ruizhi Pharmaceutical [1] - The funds will be primarily used for advancing the core drug pipeline, global patent layout for high-value innovative IP, and upgrading the computational medicine platform [1] Company Developments - Zheyuan Technology is accelerating the development of multiple drug pipelines targeting complex diseases [1] - The company is focusing on self-developed drug pipelines for diseases such as pancreatic cancer, central nervous system tumors, chordoma, and liver cancer [1]